Resolution Therapeutics reposted this
Biotech spinout Resolution Therapeutics has raised £63.5 million in Series B investment led by Syncona Limited for its macrophage cell therapy for end-stage liver disease.The company was co-founded in 2020 by Professor Stuart Forbes of the Institute for Regeneration and Repair. Dr Andrea Taylor, CEO of Edinburgh Innovations, which supported Professor Forbes through a decade of macrophage research and commercialisation, said: “The journey from lab to clinic is long and arduous and we are delighted to see Resolution approaching clinical stage. “There is currently no treatment for liver cirrhosis, apart from a liver transplant and a life on immunosuppressants, and this therapy brings cautious hope for those suffering from this neglected disease, and potentially other inflammatory conditions too.” Read more ➡️ eil.ac/ResolutionSeriesB/L #biotech #investment #liver cirrhosis #celltherapy #liverdisease #macrophagecelltherapy